MedTrace Logo

A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

NCT04188548 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2025-06-04

No results posted yet for this study

Summary

The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer or endometrial cancer.

Conditions

Interventions

DRUG

LY3484356

Administered orally

DRUG

Abemaciclib

Administered orally

DRUG

Everolimus

Administered orally

DRUG

Alpelisib

Administered orally

DRUG

Trastuzumab

Administered intravenously

DRUG

Aromatase Inhibitor (AI)

Anastrozole or Exemestane or Letrozole administered orally (physician choice)

DRUG

Pertuzumab

Administered intravenously

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-10
Primary Completion
2020-06-29
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • France
  • Japan
  • South Korea
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04188548 on ClinicalTrials.gov